This study is currently not recruiting participants.

A Phase III Randomized Double-Blind Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence

Investigating an Investigational Medication for Preventing Melanoma Recurrence

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to find out whether vemurafenib can help prevent or delay the return of melanoma that is at a high risk of returning after it has been removed surgically.

Detailed description of study

The purpose of this study is to find out whether vemurafenib can help prevent or delay the return of melanoma that is at a high risk of returning after it has been removed surgically.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Melanoma
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the use of an investigational medication to prevent or delay the return of melanoma, a type of skin cancer, in patients at high risk after surgical removal. Melanoma is a serious form of skin cancer that can spread to other parts of the body if not treated early.

Participants will be randomly assigned to different study arms to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will involve regular monitoring of the participants' health to assess the effectiveness of the treatment.

  • Who can participate: The study is open to individuals aged 18 and older who have had melanoma surgically removed and are at high risk of recurrence. Participants must meet specific health criteria to be eligible.
  • Study details: Participants will be assigned to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1211009973

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team